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Abstract: Human studies have shown diurnal rhythms of cholesterol and bile acid synthesis,
but a better understanding of the role of the circadian system in cholesterol homeostasis is
needed for the development of targeted interventions to improve metabolic health. Therefore,
we performed a systematic literature search on the diurnal rhythms of cholesterol synthesis and
absorption markers and of bile acid synthesis markers. We also examined the diurnal rhythms of
the cholesterol synthesis markers lathosterol and desmosterol, and of the cholesterol absorption
markers cholestanol, campesterol, and sitosterol in serum samples from the Bispebjerg study.
These samples were collected every three hours over a 24-h period in healthy males (n = 24) who
consumed low-fat meals. The systematic search identified sixteen papers that had examined
the diurnal rhythms of the cholesterol synthesis markers lathosterol (n = 3), mevalonate (n = 9),
squalene (n = 2), or the bile acid synthesis marker 7α-hydroxy-4-cholesten-3-one (C4) (n = 4).
Results showed that lathosterol, mevalonate, and squalene had a diurnal rhythm with nocturnal
peaks, while C4 had a diurnal rhythm with daytime peaks. Furthermore, cosinor analyses
of the serum samples showed a significant diurnal rhythm for lathosterol (cosinor p < 0.001),
but not for desmosterol, campesterol, sitosterol, and cholestanol (cosinor p > 0.05). In conclusion,
cholesterol synthesis and bile acid synthesis have a diurnal rhythm, though no evidence for
a diurnal rhythm of cholesterol absorption was found under highly standardised conditions.
More work is needed to further explore the influence of external factors on the diurnal rhythms
regulating cholesterol homeostasis.
Keywords: circadian system; diurnal rhythms; cholesterol synthesis; cholesterol absorption;
bile acid synthesis
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1. Introduction
The circadian system coordinates many physiological processes in the human body around a
24-h diurnal rhythm. This system consists of a central clock located in the suprachiasmatic nucleus
of the hypothalamus and multiple clocks in peripheral tissues, including the liver and intestines.
To regulate these rhythms, peripheral clocks combine their own rhythms with signals from the central
clock and with external factors, such as sleep and meal timing [1,2]. Evidence increasingly suggests
that misalignment between the endogenous central clock and peripheral clocks negatively influences
metabolic health. Circadian misalignment for example occurs when the sleep-wake cycle and the
light-dark cycle are not synchronized (i.e., sleeping during the day), or when feeding rhythms and
the light-dark cycle are not synchronized (i.e., eating during the night) [2]. Reviews have indeed
suggested that shift workers, who regularly experience circadian misalignment, have an increased risk
of developing the metabolic syndrome and cardiovascular disease [3,4]. Thereby, studies in healthy
non-shift workers have shown that circadian misalignment increased blood pressure, sleeping metabolic
rate, glucose, insulin, fasting plasma free fatty acids, and inflammatory marker levels, while it decreased
insulin sensitivity and leptin levels [5–8].
Cholesterol homeostasis, which is regulated by the interplay between endogenous cholesterol
synthesis, intestinal dietary and biliary cholesterol absorption, and bile acid synthesis and excretion,
is another important determinant of metabolic health [9]. Various plasma markers reflect endogenous
cholesterol synthesis (lathosterol, desmosterol, mevalonate, squalene), intestinal cholesterol absorption
(sitosterol, campesterol, cholestanol), or bile acid synthesis (7α-hydroxy-4-cholesten-3-one (C4)) in
both healthy and diseased people [10–14]. Their use as markers has been validated by analysing
relations between their plasma levels and absolute measurements of endogenous cholesterol synthesis,
intestinal cholesterol absorption, or bile acid synthesis [10–14]. It is known that cholesterol synthesis
and absorption are reciprocally related. To illustrate, increased dietary cholesterol intake has been
shown to increase cholesterol absorption, which was compensated for by a decreased endogenous
cholesterol synthesis [15]. Treatment with ezetimibe and consumption of plant sterols and stanols has
been shown to decrease cholesterol absorption, which was compensated for by an increased cholesterol
synthesis [16,17]. However, large inter-individual variation in this reciprocal relation exists and people
can be classified as cholesterol synthesizers (elevated cholesterol synthesis), cholesterol absorbers
(elevated cholesterol absorption), or intermediate [15,16,18].
Although previous studies have demonstrated a diurnal rhythm of cholesterol synthesis and bile
acid synthesis [19,20], a better understanding of the influence of the circadian system on cholesterol
homeostasis is needed for targeted interventions. Knowledge of the diurnal regulation of cholesterol
and bile acid metabolism may help determining when people should use specific dietary components
and drugs to optimize treatment and maintain in circadian alignment. Therefore, this paper had
two primary aims: 1. To give a systematic overview of the diurnal rhythms of markers reflecting
endogenous cholesterol synthesis, intestinal cholesterol absorption, and bile acid synthesis, and 2.
To examine the diurnal rhythms of cholesterol synthesis markers (lathosterol and desmosterol) and
cholesterol absorption markers (cholestanol, campesterol, and sitosterol) in serum samples from the
Bispebjerg study [21]. This study was specifically designed to examine in healthy males diurnal
rhythms of several metabolic and physiological parameters, such as LDL-cholesterol, triglycerides,
and glucose.
2. Materials and Methods
2.1. Systematic Review
2.1.1. Search Methods
The systematic review was carried out using the Preferred Reporting Items for Systematic
Review and Meta-Analyses (PRISMA) checklist [22]. The search was conducted to identify original
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research papers examining the diurnal rhythms of markers reflecting endogenous cholesterol synthesis,
intestinal cholesterol absorption, or bile acid synthesis in humans. Potentially relevant studies
were retrieved by searching the following databases: Medline, Embase, and the Cochrane Library.
Databases were searched from inception until December 2018. The Medical Subject Heading (MeSH)
terms used were: ((plant sterol OR plant sterols OR phytosterol OR phytosterols OR sitosterol OR
campesterol OR brassicasterol OR stigmasterol OR avenasterol OR lathosterol OR desmosterol OR
cholestanol OR lanosterol OR squalene OR mevalonic acid OR mevalonate OR cholesterol precursors
OR cholic acid OR chenodeoxycholic acid OR deoxycholic acid OR ursodeoxycholic acid OR lithocholic
acid OR C4 OR 7alphahydroxy4cholesten3one OR bile acid synthesis) AND (diurnal rhythm OR
circadian rhythm) AND (humans OR human)).
2.1.2. Selection Procedure
Criteria to be included were: (1) scientific papers (conference papers and posters were excluded);
(2) original studies (reviews and studies based on previously published data were excluded); (3) human
studies; (4) diurnal rhythms measured for ≥ 24 h; (5) levels of validated markers of cholesterol synthesis,
cholesterol absorption or bile acid synthesis measured; (6) markers measured in plasma or serum
(e.g., markers measured in urine were excluded); (7) at least five samples collected over a 24-h period;
and (8) studies written in English. No specific publication period was considered.
The selection procedure consisted of two rounds. In the first round, two researchers (M.M.S.
and R.P.M.) screened all the titles and abstracts of the papers obtained from the databases.
Potentially relevant articles were selected. In the second round, the full-texts of all selected papers were
read and papers that met the inclusion criteria were included. Papers that were identified through the
reference lists of the selected articles were included as well. Any discrepancies between the researchers
were resolved by discussion.
2.1.3. Data Extraction
For each included study, the following data were extracted into an Excel spreadsheet: study
information (reference number, first author, publication year), study characteristics (study design,
subgroups, study setting, study duration, time between measurements), participant characteristics (n,
age, sex, BMI, health status, medication use), marker collection (type of marker, analytical method,
measurement in serum or plasma), dietary information (type of meals, time of consumption),
sleep information (sleeping hours and conditions), and the main findings (mean marker concentrations
at the measured time points, times of peak and nadir). In case a study presented the diurnal
rhythms for each subject separately, the mean marker concentration at each time point was
calculated. If mean concentrations were not provided in a table, these were estimated from graphs
using a pixel ruler. Both absolute and cholesterol-standardised data were collected. In the end,
only cholesterol-standardised markers were used, because these have been validated to measure
cholesterol absorption, cholesterol synthesis or bile acid synthesis. Mevalonate, however, is a
water-soluble compound, and was not standardised for total cholesterol.
The marker levels measured during the first 24 h of each study were presented in graphs. First,
the 24-h period was divided into the following time blocks: 06:30–09:00 h; 09:30–12:00 h; 12:30–15:00 h;
15:30–18:00 h; 18:30–21:00 h; 21:30–00:00 h; 00:30–03:00 h; 03:30–06:00 h; 06:30–09:00 h. Second, for each
time block the median marker level measured in all studies was calculated, which was then put in
the graph.
2.2. Bispebjerg Study of Diurnal Variations
2.2.1. Subjects and Study Design
Serum samples from the Bispebjerg study were used for the analysis of cholesterol synthesis and
absorption markers. A detailed description of the study design has been published [23]. In summary,
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twenty-four Caucasian males, with a mean age of 26 years old (range 20–40 years) and mean BMI of
22.9 kg/m2 (range 19.6–24.9 kg/m2) participated in the study. Subjects spent 24 h at the hospital ward,
and standardised meals (low fat, no sugar) were provided at 09:30 h, 13:00 h, and 19:00 h. As both
high-fat and high-sugar intake may influence the circadian system [24], it was decided to use meals
that were low in fat and sugar to minimize effects on the primary outcomes of the Bispebjerg study.
Subjects slept between 23:00 h and 08:00 h in total darkness. Blood samples were collected by cubital
venepuncture every three hours from 09:00 h until 09:00 h the next day. The study was executed in
accordance with the Helsinki Declaration and written informed consent was signed by all the subjects.
Ethical approval was given by the Regional Scientific Ethical Committee of the Capital Region of
Denmark (protocol number H-B-2008-011) and the Danish Data Protection agency (journal number
2008-41-1821).
2.2.2. Serum Analyses
Serum concentrations of cholesterol, lathosterol, desmosterol, campesterol, sitosterol, and cholestanol
were determined using a gas chromatography flame ionization detector (GC-FID) as described by
Mackay et al. [25]. Lathosterol, desmosterol, campesterol, sitosterol, and cholestanol were standardised
for cholesterol concentrations (µmol/mmol cholesterol), because they are transported in serum by
lipoproteins. The lathosterol/campesterol-ratio at 09:00 h on day 1 was also calculated to classify
subjects as cholesterol absorbers (n = 8), cholesterol synthesizers (n = 8), or intermediate (n = 8).
2.2.3. Statistical Analyses
Pearson correlations were calculated to examine associations between the cholesterol absorption
and synthesis markers at 09:00 h on day 1. Cosinor analysis for populations was used to examine
whether total cholesterol, lathosterol, desmosterol, campesterol, sitosterol, and cholestanol showed a
diurnal rhythm [26,27]. A curve was fitted to the data using the following sine and cosine function:
Analyte = M + k1COS(2pit/24) + k2SIN(2pit/24) (1)
Substituting COS(2pit/24) = X and SIN(2pit/24) = Z (2)
gave the final formula: Analyte = M + k1X+ k2Z (3)
Using the GLM procedure in SAS, the model fit was tested and M, k1, and k2 were calculated.
Confidence bounds were also calculated and added to the fitted curves. The cosinor model further
estimated the mesor, amplitude, and time of peak for total cholesterol and each marker. The mesor
represents the rhythm-adjusted mean value of the cosinor curve, and the amplitude represents the
difference between the mesor and peak or between the mesor and nadir. It was concluded that a
diurnal rhythm was present when the cosinor curve was significant (cosinor p < 0.05). In addition,
linear mixed models were used to examine whether the marker levels fluctuated significantly over
time. Time was defined as fixed factor, subjects as random factor and the best model fit was based
on the lowest Akaike Information Criterion. Random intercept models with the identity covariance
structures were used. In case of significant time effects (p < 0.05), Bonferroni post hoc tests were used to
make comparisons between the marker levels at 09:00 h on day 1 and the other time points. The cosinor
analyses were conducted in SAS (SAS Institute Inc., Cary, NC, USA) and the other analyses in SPSS
version 25 for Mac OS X (SPSS Inc., Chicago, IL, USA).
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3. Results
3.1. Systematic Review
3.1.1. Study Selection
Figure 1 provides an overview of the study selection. The search yielded 204 potentially relevant
articles and 26 of these were assessed for full-text evaluation. Ultimately, 16 studies met the inclusion
criteria and their characteristics are summarized in Table 1.
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Table 1. Characteristics of studies included in the systematic review.
First
Author
(year)
Study Design Population Intervention n
Age
(years) Male (%) Marker
Study
Duration
(Hours)
Dietary Information
Type of Meals Breakfast Lunch Dinner Other
Kopito
(1982) [28]
Experimental,
crossover Healthy subjects
• One meal/day
• No meal 1 40 100 MVA 72
• Day 1 and 2:
standardised dinner
• Day 3: no meal
19:00
Miettinen
(1982) [29] Longitudinal Healthy subjects 7
Range:
16–49 N/A
Squalene
+ methyl
sterols
24
Three meals and evening snacks. Fat
intake provided approximately 35%
of total calories
08:00 12:00 16:00 20:00
Parker
(1982) [30]
Experimental,
crossover
Subject with
hyper-cholesterolemia
and ischemic heart
disease
1 55 100 MVA 72
Four daily liquid-formula meals in
equal portions; caloric intakes
adjusted to maintain BW within ± 1.5
kg over 3–5-weeks
08:00 13:00 19:00 10:00
Subject with
hypertri-glyceridemia,
obesity, and
maturity-onset diabetes
• No treatment
• 12-day fast 1 66 100 MVA 48
• No treatment: liquid formula
diet in five equal portions per
day for three weeks
• 12-day fast: no dietary intake
08:00 13:00 19:00 10:00/17:00
Subject with
heterozygous familial
hyper-cholesterolemia
and ischemic heart
disease
• Moderate
cholesterol intake
• High
cholesterol intake
1 45 100 MVA 48
• Moderate intake: five liquid
formula feedings, 550 mg
cholesterol/ day, for three weeks
• High intake: five liquid formula
feedings, 1200 mg
cholesterol/day, for three weeks
08:00 13:00 19:00 10:00/17:00
Parker
(1984) [31]
Experimental,
crossover
Subject with
hypertri-glyceridemia
• No treatment
• Moderate
cholesterol intake
• High
cholesterol intake
1 68 100 MVA 72
• No treatment: eating ad libitum
3 times/day as outpatient
• Moderate intake: five liquid
formula feedings, 207 mg
cholesterol/day, for four weeks
• High intake: five liquid formula
feedings, 972 mg cholesterol/
day, for four weeks
08:00 13:00 19:00 10:00/17:00
Miettinen
(1985) [32]
Longitudinal
Subjects with jejunoileal
bypass 4 26 ± 8 N/A Squalene+ methyl
sterols
24 Low-cholesterol diet, 125 mg
cholesterol/ 2400 kcal, 100 g fat/day
08:00 12:00 16:00 20:00
Subjects with ileal
exclusion 4 38 ± 12 N/A
Scoppola
(1991) [33] Longitudinal Healthy subjects 1 N/A N/A MVA 24 Low fat (<5%), cholesterol-free meals 09:30 12:30 19:00
Jones
(1992) [34] Longitudinal Healthy subjects 5 26 ± 4 100 MVA 48
Three self-selected, habitual
meals/day for three days prior to and
48 h during the study
08:00
–09:00
12:00
–13:00
18:00
–19:00
Pappu
(1994) [35]
Longitudinal Healthy subjects 6 30 ± 2 50 MVA 24
Three meals/day (40% fat, 25% CHO,
15% protein) 08:00 12:00 18:00
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Patients with
abetalipoproteinemia 3 24 ± 10 66.6
Three meals/ day (12–15% fat,
70–75% CHO, 13–17% protein) 08:00 12:00 18:00
Yoshida
(1994)
[36]
Longitudinal
Patients with
cholelithiasis and
patients with early
cancer of the GI-tract
3 Range:24 – 28 N/A C4 24 Normal hospital diets 08:00 12:30 17:30
Nozaki
(1996)
[37]
Experimental,
crossover
Subjects with
heterozygous familial
hypercholesterolemia
• No treatment
•
Morning pravastatin
•
Evening pravastatin
8 58 ± 9 37.5 MVA 24
Cholesterol intake ± 300 mg/day;
20% fat intake; ratio polyunsaturated
to saturated FAs was 1.5; single dose
pravastatin (20 mg) taken after
breakfast or after dinner
08:00 12:00 18:00
Pappu
(2002)
[38]
Experimental,
crossover
Subjects with
heterozygous familial
hypercholesterolemia
• No treatment
• Lovastatin
• Simvastatin
9
5
41 ± 4
N/A 0 MVA 24
Low-cholesterol, low-fat diet
conforming to phase I of the
American Heart Association Diet;
statins (40 mg) given after breakfast
and dinner for eight weeks
08:00 12:00 18:00
Martin
(2002)
[39]
Experimental,
crossover Healthy subjects
•
Morning rovustatin
• Evening rovustatin
21 N/A N/A MVA 24
Individual caloric and fat intake was
stabilized; Rosuvastatin (10 mg)
taken each morning (~07:00 h) or
evening (~18:00 h) for 14 days
N/A N/A N/A
Gälman
(2005)
[40]
Longitudinal
Healthy subjects
(n = 5) and
cholecystecto-mized
subjects (n = 3)
8 Range:25–58 50
C4,
latho-sterol 24 Standardised meals 09:00 12:00 18:00
Persson
(2010)
[41]
Experimental Healthy subjects • CME treatment 10 N/A 75 Latho-sterol 33 Standardised meals; CME was takenwith meals day 1 (4 × 4 g) 08:30 12:30 16:00 21:30
Steiner
(2011)
[42]
Longitudinal Healthy subjects 4 Range:27–29 50 C4 24 Subjects consumed identical meals
09:15
(day 1)
08:45
(day 2)
11:30 20:15
Al-Khaifi
(2018)
[43]
Experimental,
crossover Healthy subjects
• No treatment
• CME
• CME
+ atorvastatin
8 Range:20–45 100
C4,
latho-sterol 32
Standardised meals; CME (4 × 4 g)
taken before meals day 1;
atorvastatin (four daily doses of 40
mg) dose 1 and 2 taken on the
morning two days before CME
treatment, dose 3 and 4 on the
morning of the first and second
study day
08:30 13:00 18:00 20:30
Abbreviations: BW = body weight; C4 = 7α-hydroxy-4-cholesten-3-one; CHO = carbohydrates; CME = cholestyramine; FA = fatty acids; GI = gastrointestinal; MVA = mevalonate;
N/A = data not available.
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3.1.2. Lathosterol
Three papers, including five study-arms, have examined the diurnal rhythm of serum
lathosterol [40,41,43]. Two studies have examined the diurnal rhythms without treatment [40,43],
two studies following cholestyramine (CME) treatment [41,43], and one study following CME plus
atorvastatin treatment [43]. See Table S1.
In non-treated subjects, cholesterol-standardised lathosterol levels were lowest during the day
and highest during the night (Figure 2) [40,43]. A comparable pattern was observed when subjects
received CME with the meals, although cholesterol synthesis rates were increased (Figure 2) [41,43].
In one study, lathosterol levels were almost twice as high on the morning after one-day treatment with
CME compared to no treatment [43]. In contrast, lathosterol levels were decreased at all time points
following CME plus atorvastatin treatment (Figure 2) [43]. In this study, CME was given with the
meals on the first day, and atorvastatin on the morning two days before the study and on the morning
of the first and second study day [43]. On the morning of the second day, lathosterol levels were
approximately 34% lower compared to no treatment and 66% lower compared to CME alone [43].
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Figure 2. The diurnal rhythm of lathosterol levels in untreated subjects, in subjects treated with
cholestyramine (CME) alone, and in subjects treated with CME plus atorvastatin [40,41,43]. Data are
presented as medians.
3.1.3. Mevalonate (MVA)
Nine papers, including 22 study-arms, have reported on the diurnal rhythm of plasma or
serum MVA concentrations [28,30,31,33–35,37–39]. All studies examined subjects who had not
received any treatment [28,30,31,33–35,37–39], three studies examined the effects of different diets
(i.e., high cholesterol intake and fasting) [28,30,31], and three studies examined the effects of statin
treatment [37–39]. See Table S2.
MVA concentrations were lowest during the day and highest during the night and early morning
(Figure 3 ). However, two studies found lower MVA concentrations on the morning of the first day
compared with the second day [30,35] and another study did not report morning conc ntrations on the
second day [ 8], which explains the ifference in MVA concentrations between the first and second
day (Figure 3a).
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consumed for three weeks compared to lower-chole terol meals (550 mg cholesterol/day) [30].
Fasting als decreased MVA concentrations and the nocturnal p ak (Figur 3a) [28,30]. In one
study, the 24-h mean MVA concentration were significantly decreased by 55% following a 12-day fast
compared to no treatment [30]. One study [28] did not coll ct samples between 18:30 and 21:00 h and
reported lower MVA conce trations than the o her study that examined fasting [30], which exp ains the
peak in the fasting g aph (Figure 3a). Moreover, fasting MVA co centrations wer lightly decreased
in the after oon and at midnight in one study [30], as shown by the nadirs (Figure 3a).
Statin treatment decreased MVA concentrations and the nocturnal MVA peak irrespective of he
tim of administration (Figure 3b) [37–39]. The reason for t e high MVA concentrations between 06:30
and 09:00 h in the morning and evening statin group is that only one paper, that found relatively high
MVA concen ations compared with other studies (See Table S2), sampled at these time points [37].
In one study, the 24-h mean MVA concentrations were significantly decreased by 33% and 44%
following eight-week twic daily lovastatin and simv statin treatment, respectively, compared to no
treatment [38]. Lovastati dec eased the nocturnal MVA peak, which was not pre ent at all after
simvastati treatme t, and the ra io between th mean MVA night-time (20:00 h–07:00 h) to aytime
(08:00 h–19:00 h) concentration was si nificantly more re uced by simvastati (58.3%) than by lovastati
(43.8%) [38]. In another study, th 24-h area under the curv for MVA decreased by approximately
30% and 33% following 14-day orning and evening rosuvast tin tr atme t, r sp ctively, whic was
not significantly different [39]. Moreover, the MVA peak conce tration observed pre-treatment was
reduced by approximately 26% following morning rosuvastati treatment and by 31% following evening
ros vastatin treatment. These values were not tested for statistical difference [39]. Another study
showed th t a single pravastatin dose in t e morning non-significantly d creased MVA c ncentrations
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at 17:00 h, while a single pravastatin dose in the evening borderline significantly decreased MVA
concentrations at 23:00 h [37].
3.1.4. Squalene
Two papers were identified that described the diurnal rhythm of squalene. In the first study
healthy subjects were investigated, and the other studied subjects with jejunoileal bypass and subjects
with ileal exclusion [29,32]. In healthy subjects, squalene levels were lowest during the day and highest
during the night (Figure 4a) [29], as shown by the lowest squalene levels in the VLDL and HDL+LDL
fractions during the day and highest during the night. This pattern was not observed in subjects with
jejunoileal bypass nor in subjects with ileal exclusion (Figure 4b) [32]. See Table S3 and Table S4.
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3.1.5. C4
Four papers, including seven study-arms, in which the diurnal rhythm of C4 was evaluated
met the inclusion criteria [36,40,42,43]. All papers examined the diurnal rhythm of C4 without any
interventions [36,40,42,43]. One study examined cholecystectomized subjects [40], and two other
studies examined healthy subjects treated with CME alone and with CME plus atorvastatin [43].
See Table S5.
In non-treated subjects, C4 levels were highest during the day and evening, and lowest during
the night (Figure 5) [40,43]. Peaks were reported at 13:00 h, 21:00 h, 22:00 h, and between 05:30 and
07:00 h [40,43]. One study measured relatively high baseline C4 levels compared to the other time
points [43], which explains the difference in morning C4 levels between the first and seco d day
(Figure 5). Two papers only r ported absolute C4 concentr tions [36,42]. In one paper, C4 concentrations
showed a peak around 05:30 h an nadir in the evening [36], whi the oth r paper reported peaks at n on
and during the evening and night, and nadirs in the morning and afternoon [42]. In cholecystectomized
subjects, cholesterol-standardised C4 levels peaked during the day and evening (around 12:00 h,
22:30 h, and 05:30 h) [40].
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CME treatment, given with meals on the first day, ended the rhythm that had been observed
without any interventions and increased C4 levels (Figure 5) [43]. This increase had already been
observed after the first CME dose in the morning, and levels continued to increase until noon on the
second day [43]. One-day CME treatment combined with atorvastatin, which was given on the morning
two days before the study and on the morning of the first and second day, also ended the rhythm and
increased C4 levels, which was less pronounced compared to CME treatment alone [43]. The increase
had already been observed after the first CME plus atorvastatin dose in the morning of the first study
day and continued to increase until the afternoon on the second study day (Figure 5) [43]. On the
morning of the second day, C4 levels were approximately seven times higher following CME treatment
and four times higher following CME plus atorvastatin treatment, compared to no treatment [43].
3.2. Bispebjerg Study of Diurnal Variations
Table 2 shows the means ± SD and correlations between the cholesterol-standardised markers at
09:00 h on day 1. Significant negative correlations were found between lathosterol and campesterol,
lathost rol and sitosterol, nd desmo terol and cholestanol. Significant positive correlations were
found between campesterol and sitosterol, campesterol and cholestanol, and sitosterol and cholestanol.
Table 2. Mean ± standard deviation (SD) and correlations between cholesterol-standardised markers
reflecting endogenous cholesterol synthesis and intestinal cholesterol absorption at 09:00 h on day 1 in
healthy males (n = 24).
Marker Mean ± SD(µmol/mmol cholesterol) Lathosterol Desmosterol Campesterol Sitosterol
Lathosterol 1.5 ± 0.3
Desmosterol 1.0 ± 0.2 0.190
Campesterol 2.4 ± 0.8 −0.521 * −0.148
Sitosterol 1.9 ± 0.4 −0.438 * −0.309 0.868 **
Cholestanol 1.6 ± 0.3 −0.368 −0.427 * 0.755 ** 0.853 **
* p < 0.05; ** p < 0.001.
The regular day-night rhythms of the subjects were previously confirmed by analysing
the 24-h serum melatonin concentrations, which peaked at 03:34 h and were lowest in the
afternoon (cosinor p < 0.001) [23]. Total cholesterol showed a borderline significant diurnal rhythm
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(cosinor p = 0.070) and significant time-effect (p = 0.017), with the highest values during the day and the
lowest values during the night (amplitude (amp) = 0.19 mmol/L) (Figure 6a, Table 3). Of the cholesterol
synthesis markers, lathosterol has a significant diurnal rhythm (cosinor p < 0.001) and a significant
time-effect (p < 0.001), with a nocturnal peak and nadir in the afternoon (amp = 0.22 µmol/mmol
cholesterol) (Figure 6b, Table 3). Desmosterol levels remained relatively stable over time and showed
no significant diurnal rhythm (cosinor p = 0.640) or significant time-effect (p = 0.731) (Figure 6c,
Table 3). Of the cholesterol absorption markers, cosinor analysis revealed no significant diurnal
rhythms for cholestanol, sitosterol, and campesterol (cosinor p > 0.05) (Figure 6d,e,f, Table 3). Moreover,
no significant time-effect was found for cholestanol (p = 0.896), but significant time-effects were found
for sitosterol (p < 0.001) and campesterol (p < 0.001), which both showed small nocturnal peaks.
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Figure 6. The diurnal rhythms of: (a) total cholesterol (cosinor p= 0.070), (b) lathosterol (cosinor p< 0.001),
(c) desmosterol (cosinor p = 0.640), (d) cholestanol (cosinor p = 0.950), (e) sitosterol (cosinor p = 0.460),
and f campesterol (cosinor p = 0.890) in healthy males ( = 24). Data are presented as cosinor curves
with confidence bounds. The dots next to the boxplots indic t individual data points. The grey area
indicates the sleeping period and the arrows indicate meal timing. * Indicates significant difference
(p < 0.05) compared with 09:00 h on day 1 using Bonferroni post hoc tests following significant
time-effects using a linear mixed model.
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Table 3. Results of the cosinor analysis for total cholesterol, and markers reflecting endogenous
cholesterol synthesis and intestinal cholesterol absorption in healthy males (n = 24).
Marker Mesor (SE) Amplitude (SE) Peak Time (Clock Hours) Cosinor p
Cholesterol 4.18 (0.06) 0.19 (0.04) 14:08 0.070
Lathosterol 1.52 (0.03) 0.22 (0.02) 02:47 <0.001
Desmosterol 1.02 (0.01) 0.02 (0.01) 19:57 0.640
Campesterol 2.47 (0.06) 0.04 (0.04) 23:39 0.890
Sitosterol 1.97 (0.03) 0.05 (0.02) 01:57 0.460
Cholestanol 1.57 (0.02) 0.01 (0.01) 17:00 0.950
Abbreviations: SE = standard error. Data presented for cholesterol-standardised marker levels (µmol/mmol cholesterol).
The lathosterol/campesterol-ratio at 09:00 h on day 1 was used to classify subjects as cholesterol
absorbers (ratio ≤ 0.54), intermediate (0.54 < ratio < 0.73), or cholesterol synthesizers (ratio ≥ 0.73).
Overall, the 24-h patterns of lathosterol, desmosterol, cholestanol, sitosterol, and campesterol did not
differ between the groups, whereas the mean levels measured at each time point did differ between the
groups (data not shown).
4. Discussion
Based on a systematic literature search and experimental data, we conclude that plasma markers
for endogenous cholesterol synthesis and bile acid synthesis have a diurnal rhythm. No evidence was
found for a diurnal rhythm in plasma markers reflecting intestinal cholesterol absorption. The 24-h
patterns of the cholesterol synthesis and cholesterol absorption markers were not different for cholesterol
synthesizers, cholesterol absorbers, and intermediate subjects.
4.1. Endogenous Cholesterol Synthesis
Previous studies have clearly established the diurnal rhythms of plasma MVA, lathosterol,
and squalene, which show that cholesterol synthesis is lowest during the day and highest during the
night. In the Bispebjerg study, we observed a comparable diurnal rhythm of lathosterol. These findings
are in line with studies that used the deuterium incorporation method to examine the diurnal rhythm
of the cholesterol fractional synthesis rate (FSR) in healthy people [19,44,45]. These studies reported
that cholesterol FSR was lowest during the daytime and highest during the night-time. This agreement
in findings also indicates that using non-cholesterol sterol markers to measure cholesterol synthesis
is a valid method. Besides MVA plasma concentrations, urinary MVA excretion reflects HMG-CoA
reductase activity as well [46]. Interestingly, comparable diurnal patterns have been reported for
MVA plasma concentrations and urinary MVA excretion, thereby confirming that both MVA plasma
concentrations and urinary MVA excretion reflect endogenous cholesterol synthesis [28,37].
The diurnal rhythm of cholesterol synthesis is mainly regulated by 3-hydroxy-3-
methylglutaryl-CoA (HMG-CoA) reductase, which is the rate-limiting enzyme in the cholesterol
synthesis pathway [47]. The diurnal pattern of this enzyme is influenced by circadian clock
genes (e.g., Clock) and nutrition [47]. Cholesterol synthesis rates were significantly decreased in
people who consumed high-cholesterol meals compared to medium- and low-cholesterol meals,
indicating a feedback mechanism between increased dietary cholesterol intake and HMG-CoA
reductase activity [30,31,48]. The observed decrease in cholesterol synthesis rates following a period of
fasting may be attributed to a decreased expression of the sterol regulatory element-binding protein 2
(SREBP2). This is a transcription factor that activates many enzymes in the cholesterol synthesis pathway,
including HMG-CoA reductase [49]. Horton et al. has reported a decrease in nuclear forms of SREBP2 in
mice liver following a 24-h fast. Consequently, the mRNAs of several genes involved in the cholesterol
synthesis pathway were decreased by 40–70% [50]. Under normal circumstances, SREBP2 expression
is regulated by the SCAP-INSIG complex. However, when intracellular sterol concentrations are low
(e.g., during fasting), this SCAP-INSIG interaction gets disrupted [51]. Previously, it has been shown
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that SREBP2 expression during fasting is also regulated by sirtuin 1 (SIRT1) [52]. Activation of SIRT1
depends on the presence of NAD+, which acts as co-factor in this activation. During a period of fasting,
NAD+ concentrations are increased and therefore SIRT1 activity is increased as well [53]. In human
cells, it was demonstrated that activation of SIRT1 resulted in significantly reduced expression of
genes regulated by SREBP2, including HMG-CoA reductase and the LDL-receptor [52]. These findings
indicate that SIRT1 reduces SREBP2 expression during a period of fasting and can thereby lead to a
decrease in cholesterol synthesis [52].
CME treatment increased lathosterol levels, indicating that HMG-CoA reductase activity was
increased by the reduced hepatic cholesterol levels following CME treatment [41,43]. Moreover,
no major differences between morning versus evening treatment with rosuvastatin and pravastatin
in decreasing 24-h cholesterol synthesis rates were observed, which is likely due to their relatively
long half-life in plasma [37,39,54]. The type of statin had a more profound impact on the diurnal
rhythm of cholesterol synthesis, as greater reductions in 24-h MVA concentrations have been reported
following simvastatin compared to lovastatin treatment [38]. Overall, these findings emphasize that
external factors mainly influence the diurnal rhythms of cholesterol synthesis by altering the mean
24-h concentrations and maximum peak value, but not by shifting the period of maximal cholesterol
synthesis from night-time to daytime.
Surprisingly, we found no significant diurnal rhythm of desmosterol. The weak baseline correlation
between desmosterol and lathosterol combined with the finding that lathosterol and HMG-CoA
reductase activity are more strongly correlated than desmosterol and HMG-CoA reductase activity [55],
could indicate that lathosterol is the preferred marker to assess cholesterol synthesis. Furthermore,
although interventions aimed at reducing intestinal cholesterol absorption have been shown to increase
cholesterol synthesis rates, a review has suggested that plant stanol or sterol consumption increased
cholesterol-standardised lathosterol levels in 13 out of 17 interventions, while those of desmosterol
were only increased in 8 out of 17 interventions [56]. Thereby, in the studies in which lathosterol and
desmosterol both significantly increased following plant stanol or sterol consumption, this increase
in percentages was often higher in lathosterol than in desmosterol [56]. Perhaps, desmosterol levels
remain more stable over time, while lathosterol levels fluctuate more and respond more strongly to
interventions. Moreover, desmosterol is formed in the Bloch pathway, whereas lathosterol is formed in
the Kandutsch-Russell pathway. Two important enzymes in the regulation of these pathways
are 24-dehydrocholesterol reductase (DHCR-24) and 7-dehydrocholesterol reductase (DHCR-7).
Of these, DHCR-24 mediates the shift from the Bloch pathway to the Kandutsch-Russell pathway,
as well as the conversion of desmosterol to cholesterol, while DHCR-7 mediates the conversion
of 7-dehydrodesmosterol to desmosterol, as well as the conversion of 7-dehydrocholesterol to
cholesterol [57]. These enzymes are thus involved in both pathways, but the intermediates in
both pathways differ. In mice, 7-dehydrocholesterol and 24,25-dihydrolanosterol, both metabolites
in the Kandutsch-Russell pathway, had a marked diurnal pattern [58]. Thereby, a diurnal pattern
of DHCR-24 was reported in rats fed with CME and with lovastatin [59]. Although Miettinen et al.
has suggested that the absolute concentrations of certain free sterols involved in the conversion of
lanosterol to cholesterol might fluctuate over a 24-h period [29], more conclusive evidence is needed to
confirm whether metabolites in the Kandutsch-Russell and Bloch pathway, as well as DHCR-24 or
DHCR-7, are regulated by the circadian system in humans, and could thereby offer an explanation for
the different findings for lathosterol and desmosterol.
4.2. Intestinal Cholesterol Absorption
Up to now, the influence of the circadian system on human cholesterol absorption has received
little attention. In the Bispebjerg study, we found no significant diurnal rhythm of cholestanol,
campesterol, and sitosterol levels. Nevertheless, significant time effects were found for campesterol
and sitosterol, indicating that their levels did fluctuate over time, but not in a rhythmic 24-h pattern.
Animal research has shown that intestinal cells express circadian clock genes, which may control
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circadian expression of different proteins involved in cholesterol absorption [60]. However, it is
currently unknown whether the Niemann-Pick C1-Like 1 protein, essential for intestinal cholesterol
absorption [61], or the ATP-binding cassette transporters ABCG5/G8, essential for intestinal cholesterol
export [62], are under circadian regulation in humans.
A possible explanation for not finding a diurnal rhythm in cholesterol absorption may be that
subjects of the Bispebjerg study consumed low-fat meals. Dietary intake of fat and cholesterol both
influence bile acid secretion and cholesterol absorption. For example, high-fat diets increase bile acid
excretion, whereas low-fat diets reduce cholesterol absorption in humans [63,64]. Thus, it is possible
that other 24-h patterns for cholesterol absorption would have been observed in case the subjects of the
Bispebjerg study would have consumed high-fat or high-cholesterol meals.
4.3. Bile Acid Synthesis
Based on earlier studies, it is evident that C4 has a diurnal rhythm, with the lowest levels
during the night and the highest levels during the day. These findings are partly in agreement with
studies that have measured bile acid synthesis as function of CO2 output from [26-14C]cholesterol,
which reported that bile acid synthesis had one peak in the morning and was lowest during the
evening and night [20,65]. Possible reasons why only one peak has been reported in these studies could
be the small sample sizes (n = 3) and relatively complicated method to measure bile acid synthesis.
Another study in healthy males reported a mean C4 peak at noon, although C4 also peaked in the
morning in some of the subjects [66]. However, this study only collected samples for a 15-h period
(07:00–22:00 h). Thus, the nocturnal C4 levels are unknown in these subjects [66].
Previous findings have suggested that the gallbladder has a minimal role in the diurnal regulation
of bile acid synthesis, because the rhythm was comparable in cholecystectomized and healthy subjects,
and C4 concentrations measured in gallbladder bile were too low to explain the peaks in C4 [40].
Cholesterol 7α-hydroxylase (CYP7A1) is the rate-limiting enzyme in the bile acid synthesis pathway,
and can be suppressed by the fibroblast growth factor 19 (FGF19) via the farnesoid X receptor
(FXR) [67]. Thus, FGF19 and FXR may be underlying mechanisms regulating the diurnal rhythm of
C4. Studies found that postprandial increases in total and unconjugated bile acids were followed by
peaks in FGF19, which indicates that FGF19 is secreted in response to the postprandial increases in bile
acids [43,68]. Furthermore, comparable rhythms have been reported for FGF19 and C4, although peaks
in FGF19 preceded the decline of C4 [68]. A recent study has suggested that the rhythm of C4 can also
be regulated via FXR, independent of FGF19 [69]. In this study, subjects received a single dose of a
nonsteroidal FXR agonist (Px-102) and the influence of Px-102 on the diurnal rhythms of serum C4,
FXR, and FGF19 was investigated. The lowest dose caused C4 levels to decrease by 80% compared
with baseline, while FGF19 concentrations only increased when higher Px-102 doses were given.
Hence, the decrease in C4 following the lowest dose was not preceded by increased FGF19 levels,
which indicates that FXR influenced the diurnal rhythm of C4 independent of FGF19 [69]. In summary,
these findings suggest that FXR and FGF19 are both involved in the regulation of the diurnal rhythm
of C4, but the exact mechanism remains unclear.
4.4. Total Cholesterol
We did not find a significant diurnal rhythm for total cholesterol. Previous studies on the diurnal
rhythm of total cholesterol have reported conflicting findings. Some studies did not show a significant
diurnal rhythm for total cholesterol concentrations [70,71], whereas other studies did [72–74]. However,
these latter studies showed little agreement on the timing of peak concentrations, as acrophases were
reported in the morning [72], afternoon [73], and at the beginning of the evening [74]. LDL-cholesterol
may have a diurnal rhythm with peak concentrations during the day [21,74]. For HDL-cholesterol,
several studies have reported that it did not have a significant diurnal rhythm [21,70,71], while other
studies did report a significant diurnal rhythm with peaks in the afternoon [73,74].
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4.5. Discrepancies Between Studies Included in the Systematic Review
Although comparable diurnal patterns have been reported by the studies included in the review,
there were some discrepancies with regard to the average marker concentrations and timing of peaks
and nadirs. These may be explained by methodological differences between the studies, such as different
time intervals between sample collection and analytical methods. For example, one study included in
the review did not report a nocturnal MVA peak, which is probably a result of not collecting a nocturnal
sample [37]. Thereby, total cholesterol in samples from the Bispebjerg study were previously measured
using the colorimetric slide technology [21], while we used the GC-FID. Even though the concentrations
and rhythms of total cholesterol were comparable between both analytical methods, there were small
differences in the mesor, amplitude, and times of peak and nadir. Therefore, it is expected that
the different analytical methods used to measure MVA (e.g., the radio-enzymatic method and gas
chromatography-mass spectrometry (GCMS)), lathosterol (e.g., isotope dilution mass spectrometry
and GCMS), and C4 (e.g., high-performance liquid chromatography, liquid chromatography-mass
spectrometry, and gas chromatography-selected-ion monitoring mass spectrometry) may have resulted
in different concentrations, and consequently different mesors, amplitudes and times of peak and
nadir between the studies included in the review. Thereby, 14 out of 16 papers measured the diurnal
rhythms in less than ten people, which is important considering the large inter-individual variations
observed in the diurnal rhythms of cholesterol and bile acid synthesis [40,42,43,66].
The control of external factors might offer an additional explanation for the differences between
studies, e.g., meal composition, meal timing, and the number of meals per day differed between the
included studies. As dietary fat and cholesterol intake are known to influence cholesterol absorption
and cholesterol synthesis, differences in meal composition between the studies may have influenced the
rhythms. Furthermore, the impact of meal timing on the diurnal rhythm of cholesterol synthesis has
been demonstrated by Cella et al. [44]. In this study, a 6.5-h delay in meal time caused the maximum
FSR to delay with six hours after the first day, and with 8.6 h after the third day of delayed meal
times [44]. Moreover, a study in which subjects consumed meals with a similar fat and cholesterol
content, but either as three or as six meals per day, showed a significantly lower 24-h cholesterol FSR
in the subjects who consumed six meals per day [75]. This illustrates that both meal timing and the
number of meals per day influenced cholesterol synthesis patterns and rates. In addition to nutrition,
information on sleep timing and duration was missing in 12 out of 16 articles. However, sleep timing,
sleep duration, and light exposure are known to influence diurnal rhythms, and should preferably be
well aligned within and between studies to be able to make good comparisons between findings [2].
4.6. Strengths and Limitations
We combined a systematic review with an experimental study, in which serum samples were
collected under standardised conditions. This minimized the influence of between-subject variation in
exposure to external factors on diurnal rhythms. Nonetheless, the present study does have certain
limitations. Given that all serum samples in the experimental study were obtained from young and
healthy males, it is unclear to what extent the findings can be extrapolated to other populations,
especially since age- and sex-specific differences in the circadian system have been reported [76,77].
Furthermore, the cosinor analysis provided a curve in which the peak and nadir were always twelve
hours apart and small fluctuations over time were no longer detectable [23]. The additional mixed
model analyses, however, enabled us to examine whether marker levels did fluctuate significantly
over the 24-h period, though not in a rhythmic manner. In contrast to most of the studies in the
review, the Bispebjerg study had a large sample size, which is relevant considering the inter-individual
variation often reported in diurnal studies. In addition, multiple markers reflecting cholesterol
synthesis, cholesterol absorption, and bile acid synthesis were examined, thereby providing a complete
overview of the influence of the circadian rhythms on cholesterol homeostasis.
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5. Conclusions
The results of this systematic review show that both cholesterol synthesis and bile acid synthesis
have a diurnal rhythm, with a reciprocal pattern. The experimental study confirmed the diurnal rhythm
of cholesterol synthesis, which had a nocturnal peak. Although the campesterol and sitosterol levels
did fluctuate over time, no diurnal rhythm for cholesterol absorption markers was found under the
highly standardised conditions of the Bispebjerg study. This may be due to the low-fat meals consumed
by the subjects during the 24-h period. The diurnal rhythms involved in cholesterol homeostasis should
be considered when people are exposed to dietary or therapeutic interventions to prevent diseases
related to metabolic health. Future research should be carried out to further study the influence of
external factors, especially the impact of meal timing and meal composition, on the diurnal rhythms
regulating cholesterol homeostasis, as well as whether these rhythms differ for various age groups and
health conditions.
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